nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—XDH—Cisplatin—peripheral nervous system neoplasm	0.258	0.344	CbGbCtD
Pyrazinamide—XDH—Doxorubicin—peripheral nervous system neoplasm	0.173	0.231	CbGbCtD
Pyrazinamide—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0843	0.113	CbGbCtD
Pyrazinamide—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0674	0.0901	CbGbCtD
Pyrazinamide—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0442	0.059	CbGbCtD
Pyrazinamide—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0411	0.0549	CbGbCtD
Pyrazinamide—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.033	0.0441	CbGbCtD
Pyrazinamide—AOX1—Effects of Nitric Oxide—MB—peripheral nervous system neoplasm	0.0231	0.409	CbGpPWpGaD
Pyrazinamide—XDH—Effects of Nitric Oxide—MB—peripheral nervous system neoplasm	0.0215	0.38	CbGpPWpGaD
Pyrazinamide—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0189	0.0252	CbGbCtD
Pyrazinamide—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0173	0.0231	CbGbCtD
Pyrazinamide—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0118	0.0158	CbGbCtD
Pyrazinamide—Gout—Tretinoin—peripheral nervous system neoplasm	0.00218	0.0111	CcSEcCtD
Pyrazinamide—Gout—Isotretinoin—peripheral nervous system neoplasm	0.00218	0.0111	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Melphalan—peripheral nervous system neoplasm	0.00216	0.0111	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Dactinomycin—peripheral nervous system neoplasm	0.00215	0.011	CcSEcCtD
Pyrazinamide—Coagulopathy—Dactinomycin—peripheral nervous system neoplasm	0.00213	0.0109	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Tretinoin—peripheral nervous system neoplasm	0.00207	0.0106	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Isotretinoin—peripheral nervous system neoplasm	0.00207	0.0106	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Melphalan—peripheral nervous system neoplasm	0.00204	0.0105	CcSEcCtD
Pyrazinamide—XDH—Nucleotide metabolism—NME1—peripheral nervous system neoplasm	0.002	0.0353	CbGpPWpGaD
Pyrazinamide—Hepatotoxicity—Alitretinoin—peripheral nervous system neoplasm	0.00199	0.0102	CcSEcCtD
Pyrazinamide—Coagulopathy—Alitretinoin—peripheral nervous system neoplasm	0.00198	0.0101	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Topotecan—peripheral nervous system neoplasm	0.00186	0.00954	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Isotretinoin—peripheral nervous system neoplasm	0.00185	0.00946	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Tretinoin—peripheral nervous system neoplasm	0.00185	0.00946	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Cisplatin—peripheral nervous system neoplasm	0.0017	0.0087	CcSEcCtD
Pyrazinamide—Photosensitivity—Tretinoin—peripheral nervous system neoplasm	0.00168	0.00861	CcSEcCtD
Pyrazinamide—Photosensitivity—Isotretinoin—peripheral nervous system neoplasm	0.00168	0.00861	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Alitretinoin—peripheral nervous system neoplasm	0.00166	0.0085	CcSEcCtD
Pyrazinamide—Gout—Alitretinoin—peripheral nervous system neoplasm	0.00165	0.00845	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Vincristine—peripheral nervous system neoplasm	0.0016	0.00819	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Alitretinoin—peripheral nervous system neoplasm	0.00157	0.00803	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Etoposide—peripheral nervous system neoplasm	0.00156	0.00797	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Vincristine—peripheral nervous system neoplasm	0.00151	0.00774	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Cisplatin—peripheral nervous system neoplasm	0.00141	0.00725	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Alitretinoin—peripheral nervous system neoplasm	0.0014	0.00717	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Cisplatin—peripheral nervous system neoplasm	0.00134	0.00684	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Etoposide—peripheral nervous system neoplasm	0.0013	0.00664	CcSEcCtD
Pyrazinamide—Photosensitivity—Alitretinoin—peripheral nervous system neoplasm	0.00127	0.00652	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Etoposide—peripheral nervous system neoplasm	0.00122	0.00627	CcSEcCtD
Pyrazinamide—Dysuria—Tretinoin—peripheral nervous system neoplasm	0.00119	0.00611	CcSEcCtD
Pyrazinamide—Dysuria—Isotretinoin—peripheral nervous system neoplasm	0.00119	0.00611	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Tretinoin—peripheral nervous system neoplasm	0.00116	0.00596	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Isotretinoin—peripheral nervous system neoplasm	0.00116	0.00596	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Etoposide—peripheral nervous system neoplasm	0.00109	0.0056	CcSEcCtD
Pyrazinamide—Hepatitis—Tretinoin—peripheral nervous system neoplasm	0.00102	0.00523	CcSEcCtD
Pyrazinamide—Hepatitis—Isotretinoin—peripheral nervous system neoplasm	0.00102	0.00523	CcSEcCtD
Pyrazinamide—Hepatitis—Melphalan—peripheral nervous system neoplasm	0.00101	0.00516	CcSEcCtD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.001	0.0177	CbGpPWpGaD
Pyrazinamide—Hepatomegaly—Epirubicin—peripheral nervous system neoplasm	0.000952	0.00488	CcSEcCtD
Pyrazinamide—Dysuria—Alitretinoin—peripheral nervous system neoplasm	0.000904	0.00463	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Alitretinoin—peripheral nervous system neoplasm	0.000882	0.00452	CcSEcCtD
Pyrazinamide—Hepatomegaly—Doxorubicin—peripheral nervous system neoplasm	0.000881	0.00451	CcSEcCtD
Pyrazinamide—Dysuria—Vincristine—peripheral nervous system neoplasm	0.000871	0.00446	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Vincristine—peripheral nervous system neoplasm	0.00085	0.00435	CcSEcCtD
Pyrazinamide—Hepatitis—Dactinomycin—peripheral nervous system neoplasm	0.000834	0.00427	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Topotecan—peripheral nervous system neoplasm	0.000831	0.00426	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Tretinoin—peripheral nervous system neoplasm	0.000824	0.00422	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Isotretinoin—peripheral nervous system neoplasm	0.000824	0.00422	CcSEcCtD
Pyrazinamide—Malaise—Topotecan—peripheral nervous system neoplasm	0.000808	0.00414	CcSEcCtD
Pyrazinamide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000806	0.0142	CbGpPWpGaD
Pyrazinamide—Malaise—Tretinoin—peripheral nervous system neoplasm	0.000801	0.0041	CcSEcCtD
Pyrazinamide—Malaise—Isotretinoin—peripheral nervous system neoplasm	0.000801	0.0041	CcSEcCtD
Pyrazinamide—Hepatitis—Alitretinoin—peripheral nervous system neoplasm	0.000774	0.00396	CcSEcCtD
Pyrazinamide—Arthralgia—Topotecan—peripheral nervous system neoplasm	0.000763	0.00391	CcSEcCtD
Pyrazinamide—Myalgia—Topotecan—peripheral nervous system neoplasm	0.000763	0.00391	CcSEcCtD
Pyrazinamide—Arthralgia—Tretinoin—peripheral nervous system neoplasm	0.000757	0.00387	CcSEcCtD
Pyrazinamide—Myalgia—Isotretinoin—peripheral nervous system neoplasm	0.000757	0.00387	CcSEcCtD
Pyrazinamide—Myalgia—Tretinoin—peripheral nervous system neoplasm	0.000757	0.00387	CcSEcCtD
Pyrazinamide—Arthralgia—Isotretinoin—peripheral nervous system neoplasm	0.000757	0.00387	CcSEcCtD
Pyrazinamide—Discomfort—Topotecan—peripheral nervous system neoplasm	0.000753	0.00386	CcSEcCtD
Pyrazinamide—Discomfort—Tretinoin—peripheral nervous system neoplasm	0.000747	0.00383	CcSEcCtD
Pyrazinamide—Discomfort—Isotretinoin—peripheral nervous system neoplasm	0.000747	0.00383	CcSEcCtD
Pyrazinamide—Myalgia—Melphalan—peripheral nervous system neoplasm	0.000747	0.00382	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Epirubicin—peripheral nervous system neoplasm	0.000727	0.00372	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Topotecan—peripheral nervous system neoplasm	0.000716	0.00367	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Tretinoin—peripheral nervous system neoplasm	0.00071	0.00364	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Isotretinoin—peripheral nervous system neoplasm	0.00071	0.00364	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Melphalan—peripheral nervous system neoplasm	0.000701	0.00359	CcSEcCtD
Pyrazinamide—Anorexia—Topotecan—peripheral nervous system neoplasm	0.000697	0.00357	CcSEcCtD
Pyrazinamide—Anorexia—Tretinoin—peripheral nervous system neoplasm	0.000691	0.00354	CcSEcCtD
Pyrazinamide—Anorexia—Isotretinoin—peripheral nervous system neoplasm	0.000691	0.00354	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Epirubicin—peripheral nervous system neoplasm	0.000686	0.00351	CcSEcCtD
Pyrazinamide—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000684	0.0121	CbGpPWpGaD
Pyrazinamide—Anorexia—Melphalan—peripheral nervous system neoplasm	0.000682	0.00349	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Dactinomycin—peripheral nervous system neoplasm	0.000674	0.00345	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Doxorubicin—peripheral nervous system neoplasm	0.000672	0.00344	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Topotecan—peripheral nervous system neoplasm	0.000666	0.00341	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Tretinoin—peripheral nervous system neoplasm	0.000661	0.00338	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Isotretinoin—peripheral nervous system neoplasm	0.000661	0.00338	CcSEcCtD
Pyrazinamide—Malaise—Dactinomycin—peripheral nervous system neoplasm	0.000655	0.00335	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.000652	0.00334	CcSEcCtD
Pyrazinamide—Dyspepsia—Topotecan—peripheral nervous system neoplasm	0.000644	0.0033	CcSEcCtD
Pyrazinamide—Dyspepsia—Tretinoin—peripheral nervous system neoplasm	0.000638	0.00327	CcSEcCtD
Pyrazinamide—Dyspepsia—Isotretinoin—peripheral nervous system neoplasm	0.000638	0.00327	CcSEcCtD
Pyrazinamide—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.000635	0.00325	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Doxorubicin—peripheral nervous system neoplasm	0.000635	0.00325	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000631	0.00323	CcSEcCtD
Pyrazinamide—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.00063	0.00323	CcSEcCtD
Pyrazinamide—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.00063	0.00323	CcSEcCtD
Pyrazinamide—Dyspepsia—Melphalan—peripheral nervous system neoplasm	0.00063	0.00323	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.000626	0.00321	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.000626	0.00321	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Alitretinoin—peripheral nervous system neoplasm	0.000625	0.0032	CcSEcCtD
Pyrazinamide—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.000622	0.00319	CcSEcCtD
Pyrazinamide—Myalgia—Dactinomycin—peripheral nervous system neoplasm	0.000618	0.00317	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000618	0.00316	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Epirubicin—peripheral nervous system neoplasm	0.000613	0.00314	CcSEcCtD
Pyrazinamide—Discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000611	0.00313	CcSEcCtD
Pyrazinamide—Malaise—Alitretinoin—peripheral nervous system neoplasm	0.000607	0.00311	CcSEcCtD
Pyrazinamide—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.000602	0.00308	CcSEcCtD
Pyrazinamide—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.000598	0.00306	CcSEcCtD
Pyrazinamide—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.000598	0.00306	CcSEcCtD
Pyrazinamide—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000581	0.00297	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.00058	0.00297	CcSEcCtD
Pyrazinamide—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000578	0.00296	CcSEcCtD
Pyrazinamide—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000576	0.00295	CcSEcCtD
Pyrazinamide—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000576	0.00295	CcSEcCtD
Pyrazinamide—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000573	0.00294	CcSEcCtD
Pyrazinamide—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.000573	0.00294	CcSEcCtD
Pyrazinamide—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000573	0.00294	CcSEcCtD
Pyrazinamide—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000573	0.00294	CcSEcCtD
Pyrazinamide—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000569	0.00291	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Doxorubicin—peripheral nervous system neoplasm	0.000567	0.0029	CcSEcCtD
Pyrazinamide—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000566	0.0029	CcSEcCtD
Pyrazinamide—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.000565	0.00289	CcSEcCtD
Pyrazinamide—Photosensitivity—Epirubicin—peripheral nervous system neoplasm	0.000557	0.00285	CcSEcCtD
Pyrazinamide—Myalgia—Vincristine—peripheral nervous system neoplasm	0.000552	0.00283	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.00054	0.00277	CcSEcCtD
Pyrazinamide—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000539	0.00276	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000538	0.00276	CcSEcCtD
Pyrazinamide—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000534	0.00274	CcSEcCtD
Pyrazinamide—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000534	0.00274	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Cisplatin—peripheral nervous system neoplasm	0.000532	0.00273	CcSEcCtD
Pyrazinamide—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000527	0.0027	CcSEcCtD
Pyrazinamide—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000524	0.00268	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000519	0.00266	CcSEcCtD
Pyrazinamide—Malaise—Cisplatin—peripheral nervous system neoplasm	0.000517	0.00265	CcSEcCtD
Pyrazinamide—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000517	0.00265	CcSEcCtD
Pyrazinamide—Photosensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000516	0.00264	CcSEcCtD
Pyrazinamide—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000515	0.00264	CcSEcCtD
Pyrazinamide—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000513	0.00263	CcSEcCtD
Pyrazinamide—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000513	0.00263	CcSEcCtD
Pyrazinamide—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000506	0.00259	CcSEcCtD
Pyrazinamide—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000505	0.00259	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000501	0.00256	CcSEcCtD
Pyrazinamide—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000488	0.0025	CcSEcCtD
Pyrazinamide—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000488	0.0025	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Etoposide—peripheral nervous system neoplasm	0.000488	0.0025	CcSEcCtD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000485	0.00858	CbGpPWpGaD
Pyrazinamide—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000484	0.00248	CcSEcCtD
Pyrazinamide—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000483	0.00247	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000483	0.00247	CcSEcCtD
Pyrazinamide—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000478	0.00245	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000474	0.00243	CcSEcCtD
Pyrazinamide—Malaise—Etoposide—peripheral nervous system neoplasm	0.000474	0.00243	CcSEcCtD
Pyrazinamide—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000469	0.0024	CcSEcCtD
Pyrazinamide—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000465	0.00238	CcSEcCtD
Pyrazinamide—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000461	0.00236	CcSEcCtD
Pyrazinamide—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000461	0.00236	CcSEcCtD
Pyrazinamide—Rash—Topotecan—peripheral nervous system neoplasm	0.000461	0.00236	CcSEcCtD
Pyrazinamide—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000461	0.00236	CcSEcCtD
Pyrazinamide—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.00046	0.00236	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000458	0.00235	CcSEcCtD
Pyrazinamide—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000457	0.00234	CcSEcCtD
Pyrazinamide—Rash—Tretinoin—peripheral nervous system neoplasm	0.000457	0.00234	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000457	0.00234	CcSEcCtD
Pyrazinamide—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000457	0.00234	CcSEcCtD
Pyrazinamide—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000457	0.00234	CcSEcCtD
Pyrazinamide—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000455	0.00233	CcSEcCtD
Pyrazinamide—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000453	0.00232	CcSEcCtD
Pyrazinamide—Rash—Melphalan—peripheral nervous system neoplasm	0.000451	0.00231	CcSEcCtD
Pyrazinamide—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000451	0.00231	CcSEcCtD
Pyrazinamide—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000446	0.00229	CcSEcCtD
Pyrazinamide—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000442	0.00226	CcSEcCtD
Pyrazinamide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000441	0.00779	CbGpPWpGaD
Pyrazinamide—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000437	0.00224	CcSEcCtD
Pyrazinamide—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000437	0.00224	CcSEcCtD
Pyrazinamide—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000434	0.00222	CcSEcCtD
Pyrazinamide—Nausea—Topotecan—peripheral nervous system neoplasm	0.000434	0.00222	CcSEcCtD
Pyrazinamide—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000431	0.00221	CcSEcCtD
Pyrazinamide—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000431	0.00221	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000427	0.00218	CcSEcCtD
Pyrazinamide—Nausea—Melphalan—peripheral nervous system neoplasm	0.000425	0.00218	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.00042	0.00215	CcSEcCtD
Pyrazinamide—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000419	0.00214	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000417	0.00737	CbGpPWpGaD
Pyrazinamide—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000409	0.00209	CcSEcCtD
Pyrazinamide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000407	0.00208	CcSEcCtD
Pyrazinamide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000405	0.00207	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000404	0.00207	CcSEcCtD
Pyrazinamide—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000395	0.00202	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.00039	0.002	CcSEcCtD
Pyrazinamide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000389	0.00199	CcSEcCtD
Pyrazinamide—XDH—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000387	0.00685	CbGpPWpGaD
Pyrazinamide—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000386	0.00198	CcSEcCtD
Pyrazinamide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000386	0.00198	CcSEcCtD
Pyrazinamide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000377	0.00193	CcSEcCtD
Pyrazinamide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000374	0.00191	CcSEcCtD
Pyrazinamide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000373	0.00191	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00037	0.0019	CcSEcCtD
Pyrazinamide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00037	0.0019	CcSEcCtD
Pyrazinamide—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000366	0.00187	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000357	0.00183	CcSEcCtD
Pyrazinamide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000354	0.00181	CcSEcCtD
Pyrazinamide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000352	0.0018	CcSEcCtD
Pyrazinamide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000349	0.00179	CcSEcCtD
Pyrazinamide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000347	0.00177	CcSEcCtD
Pyrazinamide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000346	0.00177	CcSEcCtD
Pyrazinamide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000345	0.00177	CcSEcCtD
Pyrazinamide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000341	0.00175	CcSEcCtD
Pyrazinamide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000339	0.00174	CcSEcCtD
Pyrazinamide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000338	0.00173	CcSEcCtD
Pyrazinamide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000337	0.00172	CcSEcCtD
Pyrazinamide—Rash—Vincristine—peripheral nervous system neoplasm	0.000334	0.00171	CcSEcCtD
Pyrazinamide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000334	0.00171	CcSEcCtD
Pyrazinamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000328	0.0058	CbGpPWpGaD
Pyrazinamide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000326	0.00167	CcSEcCtD
Pyrazinamide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000316	0.00162	CcSEcCtD
Pyrazinamide—Nausea—Vincristine—peripheral nervous system neoplasm	0.000315	0.00161	CcSEcCtD
Pyrazinamide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000313	0.0016	CcSEcCtD
Pyrazinamide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000304	0.00155	CcSEcCtD
Pyrazinamide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000298	0.00152	CcSEcCtD
Pyrazinamide—Rash—Cisplatin—peripheral nervous system neoplasm	0.000295	0.00151	CcSEcCtD
Pyrazinamide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000295	0.00151	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000281	0.00498	CbGpPWpGaD
Pyrazinamide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000278	0.00142	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000273	0.0014	CcSEcCtD
Pyrazinamide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000273	0.0014	CcSEcCtD
Pyrazinamide—Rash—Etoposide—peripheral nervous system neoplasm	0.00027	0.00139	CcSEcCtD
Pyrazinamide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00027	0.00138	CcSEcCtD
Pyrazinamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000266	0.0047	CbGpPWpGaD
Pyrazinamide—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000266	0.00136	CcSEcCtD
Pyrazinamide—XDH—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000262	0.00463	CbGpPWpGaD
Pyrazinamide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000255	0.0013	CcSEcCtD
Pyrazinamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000253	0.00448	CbGpPWpGaD
Pyrazinamide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.0013	CcSEcCtD
Pyrazinamide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000251	0.00128	CcSEcCtD
Pyrazinamide—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000251	0.00128	CcSEcCtD
Pyrazinamide—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000248	0.00127	CcSEcCtD
Pyrazinamide—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.00126	CcSEcCtD
Pyrazinamide—AOX1—Disease—GNS—peripheral nervous system neoplasm	0.000243	0.0043	CbGpPWpGaD
Pyrazinamide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000235	0.00121	CcSEcCtD
Pyrazinamide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.00119	CcSEcCtD
Pyrazinamide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.00119	CcSEcCtD
Pyrazinamide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.00117	CcSEcCtD
Pyrazinamide—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000229	0.00117	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000219	0.00112	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.00112	CcSEcCtD
Pyrazinamide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.00109	CcSEcCtD
Pyrazinamide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000212	0.00108	CcSEcCtD
Pyrazinamide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000209	0.00107	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000208	0.00106	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—GNS—peripheral nervous system neoplasm	0.000203	0.0036	CbGpPWpGaD
Pyrazinamide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.00104	CcSEcCtD
Pyrazinamide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000198	0.00101	CcSEcCtD
Pyrazinamide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.001	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—NME1—peripheral nervous system neoplasm	0.000195	0.00345	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000991	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000984	CcSEcCtD
Pyrazinamide—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000978	CcSEcCtD
Pyrazinamide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000974	CcSEcCtD
Pyrazinamide—XDH—Metabolism—GNS—peripheral nervous system neoplasm	0.000189	0.00334	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—COX2—peripheral nervous system neoplasm	0.000188	0.00332	CbGpPWpGaD
Pyrazinamide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000939	CcSEcCtD
Pyrazinamide—XDH—Metabolism—NME1—peripheral nervous system neoplasm	0.000181	0.00321	CbGpPWpGaD
Pyrazinamide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000907	CcSEcCtD
Pyrazinamide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000905	CcSEcCtD
Pyrazinamide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000901	CcSEcCtD
Pyrazinamide—XDH—Metabolism—COX2—peripheral nervous system neoplasm	0.000175	0.00309	CbGpPWpGaD
Pyrazinamide—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000871	CcSEcCtD
Pyrazinamide—AOX1—Disease—PPP3R1—peripheral nervous system neoplasm	0.00017	0.003	CbGpPWpGaD
Pyrazinamide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.00084	CcSEcCtD
Pyrazinamide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000806	CcSEcCtD
Pyrazinamide—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000153	0.000783	CcSEcCtD
Pyrazinamide—Rash—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000776	CcSEcCtD
Pyrazinamide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000776	CcSEcCtD
Pyrazinamide—AOX1—Disease—ENO2—peripheral nervous system neoplasm	0.000147	0.0026	CbGpPWpGaD
Pyrazinamide—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000731	CcSEcCtD
Pyrazinamide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000724	CcSEcCtD
Pyrazinamide—Rash—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000718	CcSEcCtD
Pyrazinamide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000718	CcSEcCtD
Pyrazinamide—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000677	CcSEcCtD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000124	0.00218	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000123	0.00218	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—SLC2A1—peripheral nervous system neoplasm	0.000119	0.0021	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ENO2—peripheral nervous system neoplasm	0.000115	0.00203	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.00011	0.00194	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—BCHE—peripheral nervous system neoplasm	0.000104	0.00184	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000102	0.00181	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.93e-05	0.00176	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—TH—peripheral nervous system neoplasm	9.79e-05	0.00173	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—BCHE—peripheral nervous system neoplasm	9.68e-05	0.00171	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.24e-05	0.00163	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—TH—peripheral nervous system neoplasm	9.1e-05	0.00161	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.15e-05	0.00144	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	8.02e-05	0.00142	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GNAS—peripheral nervous system neoplasm	7.99e-05	0.00141	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ABCB1—peripheral nervous system neoplasm	7.84e-05	0.00139	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GNAS—peripheral nervous system neoplasm	7.43e-05	0.00131	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ABCB1—peripheral nervous system neoplasm	7.29e-05	0.00129	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PTPN11—peripheral nervous system neoplasm	6.63e-05	0.00117	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.29e-05	0.00111	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.5e-05	0.000973	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ERBB2—peripheral nervous system neoplasm	5.24e-05	0.000927	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.57e-05	0.000808	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.25e-05	0.000751	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—NRAS—peripheral nervous system neoplasm	3.99e-05	0.000705	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	3.98e-05	0.000703	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.81e-05	0.000674	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MYC—peripheral nervous system neoplasm	3.71e-05	0.000657	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	3.67e-05	0.000649	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.07e-05	0.000543	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	2.94e-05	0.00052	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—HRAS—peripheral nervous system neoplasm	2.92e-05	0.000516	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.83e-05	0.000501	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—AKT1—peripheral nervous system neoplasm	2.58e-05	0.000456	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	2.41e-05	0.000426	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—AKT1—peripheral nervous system neoplasm	2.16e-05	0.000381	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	2.04e-05	0.00036	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—AKT1—peripheral nervous system neoplasm	2.01e-05	0.000355	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.94e-05	0.000343	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.91e-05	0.000339	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.86e-05	0.000329	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.57e-05	0.000278	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.56e-05	0.000276	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.53e-05	0.000271	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.5e-05	0.000265	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.48e-05	0.000261	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.21e-05	0.000213	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.18e-05	0.000209	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	4.22e-06	7.46e-05	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	3.26e-06	5.76e-05	CbGpPWpGaD
